Overexpression of TRIM32 is associated with poor clinical outcomes in AML [165], and TRIM32 inhibition sensitizes glioma cells to chemotherapy by a TP53-independent pathway [166]. The gene discussed is TRIM32; the disease is acute myeloid leukemia.